Novel markers to track oxidative polysorbate degradation in pharmaceutical formulations
Sanket Dahotre1, Anthony Tomlinson1, Baiwei Lin2
1Late Stage Pharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.
Abstract:
Polysorbates can undergo oxidative degradation in pharmaceutical formulations resulting in both soluble and insoluble degradation products. The insoluble degradants may precipitate to form subvisible and visible particulates, which are undesirable in liquid parenteral products. To date, no oxidation byproduct has been identified as an established marker to track Polysorbate 20 oxidation. Herein, we identified the aldehyde derivative of free fatty acid esters as a byproduct of polysorbate oxidation that can be derivatized using 2,4-dinitrophenylhydrazine and tracked analytically to monitor oxidative polysorbate degradation in pharmaceutical formulations.
More Related Videos
Related Concept Videos
Pharmaceutical Equivalents
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Regulated Protein Degradation
Proteins: From Genes to Degradation
Transcription is the synthesis of RNA...
Proteins: From Genes to Degradation
Oxidation Numbers


